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Heart failure is a clinical syndrome caused by dysregulated calcium handling and abnormal cardiac pumping
capacity. Wahlquist et al. (2014) show that upregulation of microRNA-25 impairs calcium handling leading to
pump dysfunction and that targeting microRNA-25 using antisense oligonucleotides reverses pump dys-
function and improves survival in mice with heart failure.Heart failure is a complex clinical syn-
drome that results from a structural
and/or functional impairment(s) of the
heart muscle. Heart failure has reached
epidemic proportions in industrialized
nations and currently affects more than
20 million people worldwide (Go et al.,
2013). Despite the development of effec-
tive medical and device therapies for
heart failure, the disease ultimately pro-
gresses, leading to recurrent hospitaliza-
tions and death. Remarkably, 30%–40%
of patients die within 1 year of diagnosis
of heart failure and 60%–70% die within
5 years.
Although there have been repeated
attempts to develop a unifying hypothesis
that explains the complexity and hetero-
geneity of heart failure, no single concep-
tual paradigm has withstood the test of
time. This statement notwithstanding,
numerous studies have demonstrated
that failing human cardiac myocytes un-
dergo a number of important biological
adaptations that result in impaired cal-
cium (Ca2+) handling and decreased
contractility (Mann, 1999). Germane to
this discussion, a recent study by Wahl-
quist et al. (2014) provides new insight
into a potential role for microRNA-25
(miR-25) as an important regulator of
Ca2+ handling and contractile dysfunction
in the failing heart, whichmay have impor-
tant implications for the development of
novel therapeutics.
Excitation-contraction coupling refers
to the series of events that link depolariza-
tion of heart muscle (excitation) with the
influx of extracellular Ca2+ into the cyto-
plasm of the cardiac myocyte, which trig-
gers the release of intracellular Ca2+ from
the smooth endoplasmic reticular (sarco-
plasmic reticulum), and leads to activation
of the actin and myosin crossbridges that896 Cell Metabolism 19, June 3, 2014 ª2014enable muscle contraction. Relaxation of
cardiac muscle is facilitated by uptake of
intracellular Ca2+ into the sarcoplasmic
reticulum by the sarcoendoplasmic retic-
ulum Ca2+-ATPase (SERCA2a). Early
attempts to treat chronic heart failure
with drugs that increased Ca2+ influx into
the heart resulted in increased lethality,
at least in part, because of the deleterious
effects of increased levels of intra-
cellular Ca2+. More recent attempts to
improve excitation-contraction coupling
have included strategies to increase the
sensitivity of the actin-myosin cross-
bridges to Ca2+ as well as the use of
gene therapy to restore the expression
levels of calcium handling proteins, such
as SERCA2a, that become downregu-
lated and contribute to the progressive
pump dysfunction observed in heart fail-
ure patients.
To design new therapies to improve
excitation-contraction coupling in heart
failure, Wahlquist et al. (2014) used a
high-throughput functional screen of
human microRNAs (miRs) to identify po-
tential miRs that interact with SERCA2a.
They found that 144 miRs interacted with
SERCA2a, the most potent of which was
miR-25. In a series of logical experiments,
they demonstrated that the expression
levels of miR-25 were increased in human
heart failure as well as in an experimental
model of murine heart failure induced by
aortic constriction. They further showed
that overexpression of miR-25 in cultured
cardiac myocytes altered intracellular cal-
cium handling similar to the abnormal cal-
cium handling pattern observed in failing
human cardiac myocytes. Overexpres-
sion of miR-25 in the heart with a cardio-
tropic virus both decreased SERCA2a
levels and provoked contractile dys-
function in wild-type mice. Importantly,Elsevier Inc.miR-25 had no effect on contractility in
SERCA2a knockout mice, suggesting
that the deleterious effects of miR-25
on contractility were not secondary to
spurious off-target effects. In a re-
markable series of final experiments,
they demonstrated that injection of an
antisense oligonucleotide (antagomir)
directed against miR-25 reversed
established heart failure in mice that had
undergone aortic constriction and
improved the survival of thesemice. Over-
all, Wahlquist et al. (2014) propose a new
model (Figure 1) for altered excitation-
contraction coupling in heart failure,
wherein increased expression levels of
endogenous miR-25 leads to down-
regulation of SERCA2a, thereby pro-
voking abnormal calcium handling
and reduced pumping capacity of the
heart.
Given the magnitude of the healthcare
problems associated with heart failure,
and given the dearth of new therapeutic
agents in this area, the billion dollar ques-
tion posed by the studies by Wahlquist
et al. (2014) is whether miR-25 is a viable
therapeutic target in heart failure. Based
on first principals of rational target
development, one would expect that
the expression of miR-25 should be
increased in the failing human heart. Un-
fortunately, the extant literature is not at
all clear on this issue. The preponderance
of data, including a recent study that
quantified miR expression levels using
RNA sequencing (Yang et al., 2014), sug-
gests that miR-25 is not significantly
elevated in heart failure, which differs
from the observation by Wahlquist
et al. (2014). Thus, target validation re-
mains a significant area of uncertainty.
Another area of uncertainty is clarifica-
tion of the exact role of miR-25 with
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Figure 1. Potential Model of Dysregulated Excitation-Contraction
Coupling in Heart Failure
Tissue injury in heart failure leads to increased expression levels of microRNA-
25 (miR-25) in the heart. miR-25 binds to messenger RNA for sarcoendoplas-
mic reticulum Ca2+-ATPase (SERCA2a), which is responsible for pumping
cytoplasmic calcium (Ca2+) into the sarcoplasmic reticulum (SR) during relax-
ation of the heart. Decreased expression levels of SERCA2a result in impaired
uptake of cytoplasmic Ca2+ into sarcoendoplasmic reticulum, which leads to
diminished pumping capacity of the heart because there is less Ca2+ available
for activation of the actin and myosin crossbridges at the onset of the muscle
contraction. Sustained pump dysfunction contributes to the development of
the clinical syndrome of heart failure. Blocking miR-25 may represent a novel
strategy for improving the pumping capacity of the heart in heart failure.
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traction coupling in nonfailing
hearts. A recent study by
Dirkx et al. (2013) demon-
strated that in vivo inhibition
of miR-25 with an antagomir
provoked spontaneous con-
tractile dysfunction in mice,
which is completely opposite
to the experimental observa-
tions by Wahlquist et al.
(2014) The reason(s) for
the discrepancy between
these two studies remains
unclear, though it may relate
to the differences in antago-
mir chemistry, different (un-
known) off-target effects of
the antagomirs, the mode of
delivery of the antagomirs, or
the degree of miR-25 knock-
down that was achieved.
While theworkbyWahlquist
et al. (2014) may not
be ‘‘translatable’’ today, this
important study contributes
to the expanding body of
knowledge that supports the
importance of targeting exci-
tation-contraction coupling in
chronic heart failure. Ten
years ago, this statement
would have been viewed as
heretical because of the
disastrous results of clinical
trials that employed drugs
designed to increase cardiac
pump performance by en-
Mann, D.L. (19hancing Ca2+ entry into the heart. How-
ever, as our understanding of the molecu-
lar mechanisms associated with heart
failure has grown, and viral vectors
with cardiotropic properties have been
developed, gene therapy to introduce
SERCA2a into human cardiac myocytes
has been shown to be safe andpotentially effective in heart failure
patients (Jessup et al., 2011) and
is currently being evaluated in phase II
clinical trials (ClinicalTrials.gov Identifiers
NCT01643330 and NCT01966887). More-
over, novel classes of drugs, such
as cardiac myosin activators (omecamtiv
mecarbil) that improve excitation-contrac-Cell Metabolism 19, June 3,tion coupling in the failing
heart, are also under clinical
development (ClinicalTrials.
gov Identifier NCT01786512).
Whether specific antagomirs
that target excitation-con-
traction coupling to enhance
cardiac pump performance
can be developed to improve
the untoward clinical out-
comes in chronic heart failure
will require further investiga-
tion, but it is a clearly a
concept that is worth getting
excited about.REFERENCES
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